TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Purchased by Invesco Ltd.

Invesco Ltd. increased its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 929,743 shares of the biopharmaceutical company's stock after acquiring an additional 10,989 shares during the quarter. Invesco Ltd. owned about 0.60% of TG Therapeutics worth $27,985,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its holdings in shares of TG Therapeutics by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after purchasing an additional 209,190 shares in the last quarter. Clearbridge Investments LLC bought a new stake in TG Therapeutics during the fourth quarter valued at approximately $55,237,000. Charles Schwab Investment Management Inc. increased its holdings in TG Therapeutics by 7.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after buying an additional 84,904 shares during the last quarter. Bank of New York Mellon Corp lifted its position in TG Therapeutics by 10.5% during the fourth quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company's stock valued at $27,797,000 after purchasing an additional 87,679 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in TG Therapeutics by 7.5% in the fourth quarter. Principal Financial Group Inc. now owns 830,184 shares of the biopharmaceutical company's stock worth $24,989,000 after buying an additional 57,996 shares in the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

TG Therapeutics Stock Performance

Shares of TGTX traded up $0.87 during trading hours on Tuesday, hitting $37.84. The stock had a trading volume of 610,144 shares, compared to its average volume of 3,095,836. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.32. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The firm has a 50-day moving average price of $36.46 and a 200 day moving average price of $32.09. The firm has a market capitalization of $5.94 billion, a price-to-earnings ratio of -379.20 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. As a group, research analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TGTX. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com raised shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.